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26 Abstract: 
27 
28 Currently, out of the 82 FDA approved targeted therapies for adult cancer treatments, 
29 
30 only 3 are approved for use in children irrespective of their genomic status. Apart from 
31 
32 leukemia, only a handful of genomic-based trials involving children with solid tumors  are 
33 
34 ongoing.   Emerging   genomic   data   for   pediatric   solid   tumors   may   facilitate   the 
35 
36 development of precision medicine in pediatric patients. Here, we provide an  up-to-date 
37 
38 review of all reported genomic aberrations in the 8 most common pediatric solid   tumors 
39 
40 with whole-exome or whole-genome sequencing data (from cBioPortal database, 
41 Pediatric Cancer Genome Project (PCGP), Therapeutically Applicable Research To 42 
43 Generate  Effective Treatments (TARGET)) and additional non-WES studies.    Potential 
44 
45 druggable events are highlighted and discussed so as to facilitate preclinical and  clinical 
46 
47 research in this area. 
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9 Introduction 
10 
11 The global  incidence  of  pediatric cancers in 2012 is ~13.5 per  100,000  population   in 
12 
13 patients aged 0-19, with a mortality rate of about 12% [1]. To date, cancer is still the 
14 
15 leading cause of death in young adults and children apart from accidents. Among all 
16 pediatric cancers, solid tumors account for two-third of all cases, while  17 
18 leukemias account for the remaining one-third of cases. The most common pediatric 
19 
20 solid  tumors  include  cancers  of  the  brain  and  the  central  nervous  system   (CNS), 
21 
22 neuroblastoma, rhabdomyosarcoma, bone cancer, Wilms’ tumor as well    as 
23 
24 germ cell tumors, etc. 
25 
26 
27 
28 
29 There  are  currently  82  FDA  approved  targeted  therapies  for  the  treatment  of adult 
30 
31 cancers [2]. The clinical implementation of genomic-guided precision medicine (the   use 
32 
33 of the right drug for the right patient) based on specific tumor genetic aberrations has 34 
35 unprecedentedly extended the survival of many adult cancer patients, including those 
36 with advanced or metastatic diseases, as well as leukemias. Yet, major advances in 37 
38 improving the survival of various pediatric solid tumors are, by far, lacking. The   scarcity 
39 
40 of genomic data, especially on actionable or druggable gene mutational events presents 
41 
42 a major roadblock for the development of precision medicine for pediatric solid tumors. 
43 
44 Currently,  the  main  treatment  modalities  for  pediatric  solid  tumors  are  still surgery, 
45 
46 chemotherapy and radiotherapy. Personalized treatment options are limited. 
47 
48 
49 
50 
51 
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9 Here, we aim to provide the most up-to-date overview of genomic aberrations found in 
10 
11 pediatric  solid  tumors  from  the  public  domain  (cBioportal.org  [3,  4];  USA, Pediatric 
12 
13 Cancer Genome Project (PCGP) [5], Therapeutically Applicable Research To   Generate 
14 
15 Effective Treatments (TARGET) [6]) as well as additional published whole-genome 
16 sequencing (WGS) studies as well as other published non-WES studies for the most 17 
18 common pediatric solid tumors (all summarized in Supplementary Table 1 with original 
19 
20 references). Recent findings from several major multi-cancer pediatric clinical studies 
21 
22 are also included in this review.  We found that WES data have only been reported in   a 
23 
24 relatively small number of cases and cancer types. Among 11 most common pediatric 
25 
26 solid  tumors,  including  medulloblastoma,  glioblastoma  multiforme,  low  grade glioma, 
27 
28 neuroblastoma,  Wilms’  tumor,  osteosarcoma,  Ewing’s  sarcoma, rhabdomyosarcoma, 
29 
30 retinoblastoma, hepatoblastoma,  and germ  cell  tumors,  only  9  
31 
32 (the underlined ones) have been whole-exome or whole-genome sequenced as of today. 
33 We highlighted some potential druggable targets based on finding in adult tumors. 34 
35 Further, we also comprehensively summarized all current genomic-related clinical   trials 
36 
37 involving children  with  these cancers. This review should highlight potential   druggable 
38 
39 targets and provide insights for future development in precision medicine in pediatric 
40 
41 solid tumors. 
42 
43 
44 
45 
46 Exceptional   responders   in  pediatric   solid   tumors   shed   hope   for precision 
47 
48 medicine development 
49 
50 
51 
52 
53 3 
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to  last  for  7  months  with  partial  resolution  of  her  tumor  mass 
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9 The  success  of  precision  medicine  requires  a  good  understanding  of  the  genomic 
10 
11 aberrations in tumors that will correlate with a good clinical response to a drug   therapy. 
12 
13 To  date,  the  understanding  of  pediatric  tumor  genomics  and  how  these      genetic 
14 
15 aberrations correlate with clinical outcome is lacking. Yet, scattered reports on pediatric 
16 tumor patients showing exceptional responses to some targeted therapies [7-9]. The 17 
18 first   exceptional   response   was   reported   in   a   BRAF(V600E)-mutated      pediatric 
19 
20 glioblastoma  multiforme  patient  with  BRAF inhibitor  vemurafenib,  whose     complete 
21 
22 response lasted for 6 months [7], as well as BRAF(V600E)-mutated metastatic  rhabdoid 
23 
24 meningioma treated with a BRAF inhibitor, dabrafenib, whose response was reported 
25 
26 [8].  Other  than BRAF- 
27 
28 mutated tumors, Zapletalova et al reported a 16 months of complete response from a   9 
29 
30 year   old   tuberous   sclerosis   complex   (TSC)   patient   with   malignant perivascular 
31 
32 epithelioid cell tumor (PEComa) carrying germline mutation of the PDGFR-alpha [9]. 
33 These emerging reports of exceptional responders in pediatric patients whose treatment 34 
35 was decided based on their tumor genomic profile do implicate the potential promise   of 
36 
37 precision medicine for pediatric solid tumors. 
38 
39 
40 
41 
42 WES studies in pediatric solid tumors reveal several potential druggable targets 
43 
44 
45 As illustrated in adult cancers, whole-exome sequencing (WES) of tumor tissues reveals 
46 important druggable targets for treatment and future drug development. The mutational 47 
48 profiles of adult cancer provide a genomic roadmap, prompting both preclinical and 
49 
50 clinical development of precision medicine in adult cancers. As for pediatric solid  tumors, 
51 
52 
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54 
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9 due to the rarity of the diseases, WES studies are challenging to be conducted with a 
10 
11 number of samples. Yet, as of today, out of the 11 most common pediatric solid  tumors, 
12 
13 there   are   published   genomic   data   of   eight   of   these   tumor   types,      including 
14 
15 medulloblastoma, glioblastoma multiforme, low grade glioma, neuroblastoma, Wilms’ 
16 tumor, osteosarcoma, Ewing’s sarcoma and rhabdomyosarcoma (Supplementary Table 17 
18 1) [10-44]. As for the remaining 3 solid tumor types (retinoblastoma, hepatoblastoma, 
19 
20 germ  cell  tumors),  though  no  large  scale  WES  has       been 
21 
22 performed, we have included genomic events from other non-WES studies in order to 
23 
24 provide a better profile of all 12 pediatric tumor types concerned. 
25 
26 Based on these WES data of pediatric tumors and the existing published  drug-response 
27 
28 reports  from  adult  patients,  several  currently  druggable  targets  are  highlighted     in 
29 
30 Supplementary   Table   1.   Mutational   events   of   >3%   rate   of   occurrences   were 
31 
32 summarized (original data are available in the original references).  In  medulloblastoma, 
33 
34 among the 254 whole-exome sequenced cases, there are no immediate actionable or 
35 
36 druggable events with >3% rate. Whilst for glioblastoma multiforme (GBM; 606 cases 
37 
38 sequenced total, representing the largest tumor cases sequenced among the 11 most 
39 
40 common pediatric solid tumors), several prominent drug targets with mutational    events 41 
42 have been identified. Due to the fact that only 6 of the 606 GBM tumors were from 
43 children (age 0-18), there are little implications for pediatric GBM treatments until the 44 
45 genomic information of a large enough pediatric GBM cohort is available. Yet, as of 
46 
47 today, based on this tumor type, there could be several druggable targets, including 
48 
49 EGFR,  PIK3CA,  NF1,  IDH1  and  IDH2  mutations.  However,  among  the  95    EGFR 
50 
51 mutations reported in GBM patients, only one mutation has been previously reported   to 
52 
53 5 
54 
55 
56 
57 
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9 be associated with gefitinib sensitivity in lung cancer patients [45]. This finding  indicates  
10 
11 the presence of drug-sensitive mutant of EGFR, though in a very small number of   GBM 
12 
13 patients. Further, hotspot and activating mutations of PIK3CA (including E542K,  E545K, 
14 
15 and H1047R) are also present in 9 patient tumors, implicating potential sensitivity to 
16 PI3K pathway inhibitors. It remains to be determined if NF1 mutations, which will drive 17 
18 tumorigenesis via the Ras pathway, can be targetable with MAPK pathway inhibitors in 
19 
20 pediatric cancers or not, given the conflicting data in several tumor types. In  melanoma, 
21 
22 though NF1 mutations are common, recent studies suggest that NF1 mutations may  not 
23 
24 predict for MEK inhibitor sensitivity [46]. However, a recent report demonstrated  marked 
25 
26 clinical responses of a NF1-mutated neurofibromatosis-associated glioblastoma case  to 
27 
28 tremetinib,  a MEK inhibitor   [47].   A recent  clinical  trial  on  Neurofibromatosis Type 1- 
29 
30 Related Plexiform Neurofibromas also showed high rates of clinical responses (70% 
31 
32 cases) to another MEK inhibitor, selumetinib, among pediatric patients [48]. 
33 
34 
35 
36 Lastly, there are 15 GBM patient tumors (5.2%; 15/290 cases) harboring IDH1 hotspot 
37 
38 mutation (R132H/G), which may confer sensitivity to IDH1-mutant specific inhibitor,  AG- 
39 
40 120,  under  development  in  clinical  settings.  The  IDH1  and IDH2 genes  encode  the 
41 
42 enzymes isocitrate dehydrogenase 1 and 2, respectively. Normal wildtype IDH  enzymes 
43 
44 are  responsible  to  generate  energy  for  cells  by  breaking  down  the  cell  nutrient, α- 
45 
46 ketoglutarate. Recent studies in multiple cancer types reveal that IDH1/2 mutations   can 
47 
48 serve as new therapeutic targets since IDH1/2 mutations can switch the cancer cell 
49 
50 energy programming and produce the oncogenic metabolite, 2-hydroxyglutarate (2-HG), 
51 as well as dysregulating cell differentiation. An important glioma study by Rohle et al 52 
53 6 
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9 showed that a mutant specific inhibitor of IDH1 (R132H), namely AGI-5198, which   have 
10 
11 been identified through a large-scale drug screen, was able to effectively inhibit the 
12 
13 mutant IDH1 activity, resulting in marked inhibition of IDH1-mutant glioma cell growth 
14 
15 and promoted glioma cell differentiation [49, 50]. Currently, there are several ongoing  
16 clinical trials investigating the safety profile and potential clinical efficacies of IDH1- 17 
18 mutant specific inhibitors (e.g. AG-120, an oral selective inhibitor that inhibits mutated 
19 
20 IDH1  protein)  in  glioma  and  other  cancers.  Results  show  early  promises  in glioma 
21 
22 patients (however, age of patients have not been disclosed) with some cases of stable 
23 
24 disease beyond six months [51]. Similar to IDH1 mutation, clinical trials are ongoing to 
25 
26 determine the safety profile and potential efficacy of IDH2 mutant inhibitor (AG-221) in 
27 
28 patients with blood cancer (acute myeloid leukemia). 
29 
30 
31 
32 
33 For  low  grade  glioma,  mutant  IDH1,  IDH2,  PIK3CA,  NF1,  BRAF,  and  FGFR1  are 34 
35 potential drug targets with a >3% rate (Supplementary Table 1). Similar to glioblastoma 
36 multiforme, IDH1, IDH2, PIK3CA, NF1 are potentially druggable with IDH1/2-mutant 37 
38 specific inhibitors, PI3K pathway inhibitor and MAPK pathway inhibitors, respectively.   It 
39 
40 is noticeable that 221/289 cases of low grade glioma tumors harbored IDH1(R132X) 
41 
42 hotspot  mutations  AG-221,  which  can  be  druggable  with  an  IDH1-mutant    specific 
43 
44 inhibitors  AG-120. Also, there are 4.2%  (12/286 cases)  of patients with IDH2    hotspot 
45 
46 mutations  (R172X),  which  can  be  potentially  druggable.  Notably,  as  high  as 21.3% 
47 
48 cases of low grade glioma harbor FGFR1 gene duplication or activating gene fusion 
49 
50 (FGFR1-TACC3 fusion)  or mutation, implicating this  subset of FGFR1-altered   patients 
51 
52 can be potentially sensitive to FGFR inhibition [52]. Further, BRAF(V600E) activating 
53 7 
54 
55 
56 
57 
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9 mutation occurs  in low grade  glioma patient  at  a rate of  0.35%  (TCGA,    Provisional) 
10 
11 which confers sensitivity to vemurafenib or BRAF inhibitors. Lastly, there are 6 cases 
12 
13 with hotspot activating mutations of PIK3CA (E542K, E545K/A, and H1947R/L) which 
14 
15 can also be potentially druggable with PI3K pathway inhibitors, while no drug-sensitive 
16 EGFR activating mutations have been identified in low grade glioma patients thus far. 17 
18 There  are  quite  a  number  of  druggable  mutations  to  be  potentially  tested  in   both 
19 
20 preclinical and clinical settings for this tumor type. 
21 
22 
23 
24 
25 In neuroblastoma, ALK genetic aberrations (amplification, gain, deletion, point mutations, 
26 
27 etc.)   have  been  reported in 6-9%  cases by WES conducted  in  the  US and    Europe 
28 
29 (Supplementary Table 1) [53, 54]. However, an Egyptian study report an exceptional 
30 
31 high rate of ALK aberrations in 50% of patients [55].  Yet, most of these  neuroblastoma- 
32 
33 associated  ALK  aberrations  are  not  related  to  sensitivity  to  ALK  inhibitors  as  ALK 34 
35 inhibitor sensitivity is known to be contributed mainly by ALK gene rearrangements as 
36 largely reported in lung cancer patients. Rather, a subset of neuroblastoma patients 37 
38 whose tumor  harbor  the  resistant  mutation, ALK(F1174V)  are likely to be resistant   to 
39 
40 ALK inhibitors. 
41 
42 
43 
44 
45 For retinoblastoma, RB1 and RBL2 mutations are the only mutated genes, which are 
46 
47 currently undruggable. However, amplification of MYCN been reported in some cases  of 
48 
49 retinoblastoma and may serve as drug targets for MYCN-Aurora A dual inhibitor,  CD532 
50 
51 
52 
53 8 
54 
55 
56 
57 
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9 [56]. WES of Wilm’s tumor, thus far, do not reveal any noticeable drug targets, while  
10 
11 MYCN amplification may serve as a potential druggable event. 
12 
13 
14 
15 
16 No WES have been conducted for hepatoblastoma, however, other non-WES studies 17 
18 revealed that PIK3CA mutations (2.1%; 1/47 cases) can potentially be druggable with 
19 PI3K pathway inhibitors (e.g. BYL719, BKM 120, everolimus, etc.), which are in later 20 
21 phases of clinical trials in adult cancers. For osteosarcoma, WES did not reveal any 
22 
23 apparent drug targets. Yet, non-WES studies indicate that MYC, MDM2 and VEGFA 
24 
25 amplifications  can  potentially be  targeted  with  MYC  inhibitors, MDM2 inhibitors,   and 
26 
27 VEGF  or  VEGFR  inhibitors,  respectively.  As  MYCN  amplification  appears  to  be   a 
28 
29 noticeable target for several pediatric solid tumors, the potential benefit of metronomic 
30 
31 topotecan may also be investigated as previous studies demonstrated high topotecan 
32 
33 sensitivity in MYCN-amplified cell models (neuroblastoma [57]), and this agent has been 34 
35 shown to be effective for childhood cancer with safe clinical profile [58]. 
36 
37 
38 
39 Two large scale Ewing’s sarcoma WES studies reveal a lack of druggable mutations 
40 
41 with a >3% occurrence rate [32, 33]. Note that there are ~2% of PIK3CA mutations 
42 
43 (V344G, K733G), however, it is unclear if these mutations can confer sensitivity for PI3K 
44 
45 targeting  or  not.  For  rhadomyosarcoma,  though  genomically  aberrations  of      NF1, 
46 
47 PIK3CA and  FGFR4 genes  are  potential  druggable  targets,  detailed  analysis  of  the 
48 
49 FGFR4 events (V550L/M mutations in 3 tumors (out of 43 cases sequenced),  preclinical 
50 
51 prediction suggest that this mutation is likely a gatekeeper mutation that may not   confer 
52 
53 9 
54 
55 
56 
57 
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9 sensitivity to a FGFR4 inhibitor, BLU9931 [59]. However, new FGFR inhibitors may be  
10 
11 developed to overcome such a resistance mechanism in the future. 
12 
13 
14 
15 
16 WES  data  are  available  for  germ  cell  tumors  (TCGA  Provisional,  via  cbioportal). A 17 
18 prominent drug target is KIT, which is mutated in 18.8% of germ cell tumors. Mutations 
19 in exon 11 of KIT (juxtamembrane domain of KIT spanning amino acids 550-591) are 20 
21 known to confer sensitivity for imatinib in GIST and melanoma [60]. In this TCGA  cohort 
22 
23 of germ cell tumors, a total of 8 exon 11 KIT mutations have been identified, including 
24 
25 W557G/C/R (4 patients), and G565_T574delinsA, V560G, L576P, Y578C and K642E  (1 
26 
27 patient each). Notably, L576P and K642E have been reported to be associated with 
28 
29 durable  partial  or  complete  responses  to  imatinib  in  melanoma  [60],  while  18   KIT 
30 
31 mutations are associated with imatinib-resistance (D816X), which may be sensitive to 
32 
33 other tyrosine kinase inhibitor, such as PKC412 [61] as shown in vitro settings.       From 34 
35 this provisional genomic data of germ cell tumors, it appears than other than KIT, there 
36 is a paucity of druggable mutations. Though driver gene mutations such as KRAS and 37 
38 NRAS hotspot mutations (G12S/D, Q61X) are common in germ cell tumors, but they are 
39 
40 not readily druggable  yet. 
43 
44 
45 
46 
47 These WES data from specific tumor types show that some genetic subsets of these 
48 
49 pediatric patients may be responsive to some targeted therapies already approved for 
50 
51 adult cancers or to agents currently undergoing clinical trials for adult patients. In fact, 
52 
53 10 
54 
55 
56 
57 
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9 the two exceptional responder cases [7, 8] demonstrated potential clinical responses   in 
10 
11 pediatric patients for precision medicine based on their tumor mutational profiles.   Thus, 
12 
13 it  becomes  increasing  important  to  conduct  more  pediatric  clinical  trials  based   on 
14 
15 patients’ tumor genetics. Recently, three important clinical studies investigating practical 
16 clinical implementation of sequencing into clinical management of pediatric cancers 17 
18 from the University of Michigan [62], from Texas Children’s Cancer Center [63], as    well 
19 
20 as  from  Dana-Farber   (the  Individualized  Therapy  (iCat)  study,  [64])  showed  that a 
21 
22 substantial   percentage  of   pediatric   solid  tumor  patients  (~40%)   have    potentially 
23 
24 actionable genomic aberrations. 
25 
26 
27 
28 
29 Anticipating more WES data for more pediatric solid tumors 
30 
31 It is important to note that several WES projects on pediatric cancers are in progress, 
32 
33 which will further inform us the druggable genetic profiles of pediatric solid tumors. 34 
35 These include the Pediatric Cancer Genome Project by St. Jude Children’s Research 
36 Hospital and Washington University (sequencing 13 types of solid tumors including 37 
38 brain  tumors,  neuroblastoma,  retinoblastoma  and  Wilms’  tumor)  [5].  Some  of these  
39 
40 WES data, including those of medulloblastoma [12], retinoblastoma [20],   osteosarcoma 
41 
42 [30], adrenocortical tumors [65], low grade neuroepithelial tumor[66], high grade   glioma 
43 
44 [67] and low grade glioma [16] had been published. Another ongoing effort is that of   the 
45 
46 TARGET program by the Office of Cancer Genomics of the National Cancer Institute, 
47 
48 which   is   currently   sequencing   several   tumor   types   (including      neuroblastoma, 
49 
50 osteosarcoma  and  kidney  tumors  including  Wilms’  tumor,  clear  cell  sarcoma  of the 
51 
52 kidney, congenital mesoblastic nephromas and rhabdoid tumor) [6]. The program had 
53 11 
54 
55 
56 
57 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
University   of   Michigan   Pediatric   Michigan   Oncology   Sequencing   study   (PEDS- 
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9 published WES data on neuroblastoma [19], Wilms’ tumor [24], clear cell sarcoma of the  
10 
11 kidney [68] and rhabdoid tumor [69]. It is worth noting that most of these WES studies 
12 
13 were performed as single studies, primarily involving Caucasian subjects. It is  important 
14 
15 that additional WES or even whole-genome sequencing (which can effectively identify 
16 large gene fusion events potentially missed by WES) studies on pediatric solid tumors 17 
18 derived from other patients of diverse ethnic backgrounds are performed to enhance our 
19 
20 understanding of the genomic aberrations associated with these pediatric cancers. 
21 
22 
23 
24 In addition to these above-mentioned large-scale genomic characterization studies for 
25 
26 specific  pediatric  tumor  types  which can inform  us  both the underlying cancer biology 
27 
28 involved as well as potential treatment directions, several large scale clinical studies  are 
29 
30 ongoing to actively investigate various practical aspects and clinical outcomes of  clinical 
31 
32 implementation of genomics-guided precision medicine for pediatric solid tumors. These 
33 include: 1) the Baylor Advancing Sequencing into Childhood Cancer Care (BASIC3) 34 
35 study  for  children  with  newly  diagnosed  solid  tumors  and  brain  tumors  [70],  2) the 
36 
37 
38 
39 
40 
41 
42 
43 iCat  follow-up  study,  called  the Genomic  Assessment  Informs  Novel  therapy (GAIN) 
44 
45 consortium study,  which  will perform specialized tumor profiling for newly diagnosed, 
46 
47 recurrent, as well as refractory solid tumors (NCT02520713) together  with iCat    clinical 
48 
49 recommendations  for clinical  management,  and 4)  the multi-institutional INdividualized 
50 
51 Therapy FOr Relapsed Malignancies in Childhood (INFORM) study, which is a   German 
52 
53 12 
54 
55 
56 
57 
 
 
 
 
 
 
 
 
 
 
 
 
MIONCOSEQ; [71], which includes an integrative sequencing approach to examine all 
genetic  variants,  fusions,  gene  copy  changes  into precision medicine decision,  3)  the 
 trials, and probably also inform us on related longer-term efficacy and toxicity issues for 
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9 program coordinated  through  the German Cancer  Research Center (German    Clinical 
10 
11 Trials Register, Study ID: DRKS00007623) for precision treatment of high-risk  refractory 
12 
13 or relapsed pediatric cancers including solid tumors [72]. Molecular profiling includes 
14 
15 WES, WGS, RNA sequencing, methylation and expression array profiling. 5) Lastly, the 
16 Children’s Oncology Group (COG)-National Cancer Institute (NCI) are launching a 17 
18 collaborative  trial  called  the  COG-NCI  Pediatric  Molecular  Analysis  for Therapeutics 
19 
20 Choice  (Pediatric  MATCH)  in  2017  [73].  This  trial  employs  an  umbrella design with 
21 
22 multiple single-arm trials for  patients  with matched molecular  profiles  to be put  on     7 
23 
24 classes  of  selected  molecular  targeting  agents  at  the  initial  phase.  Importantly, the 
25 
26 efficacy  and  safety  of  these  agents  have  been  carefully  reviewed  by  the  Pediatric 
27 
28 MATCH Target and Agent Prioritization (TAP committee).  These 7 classes of  molecular 
29 
30 targeting agents include inhibitors for mTOR/PI3K, MEK, PDGFR-alpha, BRAF, ALK, 
31 
32 TRK and FGFR [73]. The results of these major ongoing clinical studies are highly 
33 anticipated as it will start teaching us about pediatric responder genomics as in adult 34 
35 
36 
37 young  cancer  patients.  Some  early  results  from  these  several  studies  have    been 
38 
39 recently  published  and  we  have  summarized  those  major  findings  in  the   “towards 
40 
41 precision treatment for pediatric solid tumors” section below. 
42 
43 
44 
45 
46 Current Targeted Therapies for Pediatric Solid Tumors 
47 Although there are 82 targeted therapies approved by the US FDA for the treatment of 48 
49 adult cancers, only 3 of these drugs have been approved for use in children  (everolimus, 
50 
51 dinutuximab and denosumab) irrespective of the genomic status of the tumors. For the 
52 
53 13 
54 
55 
56 
57 
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5 
6 
7 
8 
9 11  pediatric  solid tumors  shown in Supplementary Table 1, only everolimus  has  been 
10 
11 approved  for  the  treatment  of  subependymal  giant  cell  tumor  for  both  children and 
12 
13 adults, dinutuximab for neuroblastoma for both children and adults, and denosumab   for 
14 
15 giant cell tumor in skeletally mature adolescents and adults (Table 1). Besides children 
16 with neuroblastoma and giant cell tumor, pediatric patients with the remaining 10 tumor 17 
18 types listed have no new treatment options other than the conventional therapies. Two  
19 
20 additional   drugs   have   been   approved   for   adults   with   glioblastoma    multiforme 
21 
22 (bevacizumab)    and    rhabdomyosarcoma    (pazopanib)    and    Hodgkin’s  lymphoma 
23 
24 (brentuximab) but not for children with the same cancer types. 
25 
26 
27 
28 
29 Everolimus is a kinase inhibitor approved for the treatment of subependymal giant cell 
30 
31 astrocytoma  (SEGA)  associated  with  tuberous  sclerosis  in  children  [74].  A  phase 3 
32 
33 randomized,  double-blind,  placebo  controlled  trial  (EXIST-1)  in  pediatric  and    adult 34 
35 patients (N=117; median age 9.5 years) showed 27 out of 78 (35%) patients receiving 
36 everolimus had at least 50% reduction in tumor size at 6 months in the absence of new 37 
38 or  worsening  non-target  SEGA  lesions,  or  new  or  worsening  hydrocephalus[75].  A 
39 
40 recent long-term  follow-up study showed  that with 60 months of  everolimus’ use,     52- 
41 
42 60% of patients demonstrated SEGA volume reduction of >30-50% [75]. 
43 
44 
45 
46 
47 Dinutuximab, also called Ch14.18, is a GD2-binding monoclonal antibody, which has 
48 
49 been recently approved by the FDA as part of the first-line therapy for patients with 
50 
51 high-risk  neuroblastoma.  It  has   been   approved  to  be   used  in  combination     with 
52 
53 14 
54 
55 
56 
57 
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9 granulocyte-macrophage  colony-stimulating  factor  (GM-CSF),  interleukin-2  (IL-2) and 
10 
11 13-cis-retinoic acid (RA) for the treatment of pediatric patients with neuroblastoma   [76].  
12 
13 Its  efficacy  is  demonstrated  in  a  phase  3  randomized,  open-label,  multicenter  trial 
14 
15 (N=226; median age 3.8 years). In patients receiving the dinutuximab regimen (six 
16 cycles of isotretinoin and five concomitant cycles of dinutuximab in combination with 17 
18 alternating GM-CSF and interleukin-2) vs isotretinoin treatment alone, the event-free 
19 
20 survival  and  overall  survival  after  2  years  was  66%  and  86%  (vs.  46%  and 75%, 
21 
22 respectively) [77]. 
23 
24 
25 
26 
27 Denosumab   is   a   monoclonal   antibody   against   RANKL,   which   is        aberrantly 
28 
29 overexpressed in giant cell tumor of bone (GCTB) in skeletally mature   adolescents[78]. 
30 
31 It has been approved by the FDA (under the priority review program) as the first and  the 
32 
33 only  approved  drug  for  GCTB  in  2013.  The  approval  was  based  on  the      clinical 34 
35 effectiveness and safety revealed from two clinical trials on 305 patients of which 10 
36 were skeletally mature adolescents with GCTB. It showed an overall objective response 37 
38 rate in 2 out of 6 patients (33%) using modified Response Evaluation Criteria in Solid 
39 
40 Tumors (RECIST 1.1) [79]. 
41 
42 
43 
44 
45 These 3 FDA approved targeted therapies have proven to be of use in solid tumors 
46 
47 unresponsive to standard treatment in children, leading to a significant improvement in 
48 
49 survival. 
50 
51 
52 
53 15 
54 
55 
56 
57 
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9 Towards precision treatment for pediatric solid tumors 
10 
11 Gene-based clinical trials in pediatric solid tumor patients are challenging to conduct, 
12 
13 mainly due to the very small number of childhood cancer patients in any single center. 
14 
15 Further, the efficacy and clinical details for precision medicine implementation in 
16 pediatric oncology have not been well-established yet. Recently, several large scale 17 
18 studies  have  started  to  investigate  various  clinical  aspects  and  issues  related     to 
19 
20 implementation of precision medicine for pediatric solid tumors Major findings include:  1) 
21 
22 with genomic profiling including WES, WGS, or targeted sequencing, up to 32-56% of 
23 
24 pediatric  patients   with   solid   tumors   had   potentially  druggable/actionable genomic 
25 
26 aberrations [62-64, 72, 73, 80-82]. 2) Such actionable findings have impacted cancer 
27 
28 management in several noticeable ways, including changes in drug therapies based   on 
29 
30 somatic  or  germline  mutations  identified  (even  for  refractory  cases  with  no     more 
31 
32 treatment options), changes in diagnosis, consideration or provision of genetic 
33 counseling, and genetic testing of at-risk siblings. 3) Among some of the “precision- 34 
35 treated  patients”,  very   promising  clinical   responses,  including  complete  or    partial 
36 
37 durable responses were observed in some very rare pediatric solid tumors with ALK 
38 
39 inhibitors  (for  ALK  or  MET  rearrangements),  BRAF  or  MEK  inhibitors  (for      BRAF 
40 
41 mutation or rearrangement), with panzopanib (for TFE3 rearrangements), and   sirolimus 
42 
43 (for PIK3CA mutation), etc (details summarized in Table 2). 4) Potentially limited by   the 
44 
45 lack  of  previous  evidence  of  gene-drug  sensitivity  data  in  these  rare  cancers   and 
46 
47 scarcity of drugs with previous toxicity data in children, some patients were not treated 
48 
49 with new drug options even with known genomic profiles. Therefore, it becomes clear 
50 that increasing the availability of targeted therapies for young patients with more 51 
52 
53 16 
54 
55 
56 
57 
 Page 17 of 33 Future Oncology 
 
 
1 
2 
3 
4 
5 
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7 
8 
9 extensive  toxicity  profile  information  may  provide  clinical  benefit  for  them.  It  is 
10 
11 anticipated that  these  ongoing multi-center, multi-cancer  type trials in young   patients, 
12 
13 including the  PEDS-MIONCOSEQ,  BASIC3,  iCat follow-up  study,  INFORM, Pediatric- 
14 
15 MATCH, will offer further practical insights and provide strong evidence-based clinical 
16 rationale for implementation of precision medicine in the near future, potentially with 17 
18 improved clinical  outcomes  for these young patients. Among those, clinical    outcomes 
19 
20 from umbrella trials are highly anticipated. 
21 
22 
23 
24 
25 In  addition  to  these  large  scale  clinical  studies  dedicated  to  pediatric  solid    tumor 
26 
27 patients,  there  are some  pediatric-inclusive trials investigating the  clinical  efficacies of 
28 
29 drugs or drug combinations targeting five genetic alterations, namely BRAF, EGFR, 
30 
31 ALK,  ROS1  and MET  in various tumor  types (Table 343a).  Some of  these     ongoing  
32 
33 clinical trials include young adults aged 16 or above. Most of these clinical trials have 34 
35 not reached phase 3, except for vemurafenib, which is tested in adolescents aged 16 or 
36 above. Especially for EGFR alterations, it is known in adult non-small cell lung cancer 37 
38 (NSCLS)  that  only EGFR-activating mutations will confer  sensitivity to EGFR   tyrosine 
39 
40 kinase inhibitors (TKIs). It remains to be examined in these pediatric drug trials if   EGFR 
41 
42 gene amplification or EGFR overexpression may identify pediatric responders to   EGFR 
43 
44 inhibitors.  Similarly,  whilst  ALK targeting  has  been  shown  to  be  effective in NSCLC 
45 
46 patients  with ALK-gene rearrangements,  it  remains  to  be  examined in pediatric  drug 
47 
48 trials if ALK inhibitors would be effective in ALK-altered pediatric tumors. The results of 
49 
50 these  gene-based  clinical  trials  are  highly  anticipated  as  new  options  for   pediatric 51 
52 patients may be identified. 
53 17 
54 
55 
56 
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11 Ongoing clinical trials for targeted therapies for pediatric solid tumors 
12 
13 
14 Besides genomic-guided clinical trials, trials addressing the efficacy of specific  targeting 
15 
16 of the EGFR, IGF1R and PI3K pathways with no specified gene analysis in the trial 17 
18 designs are also underway (Table 4). Most trials are in early stages, except for a phase 
19 3 clinical trial of nimotuzumab (a humanized monoclonal antibody against EGFR; 20 
21 NCT00561691)   in   diffuse   pontine   glioma.   In   neuroblastoma,   a   phase   I   study 
22 
23 (NCT02337309) is testing the use of SF1126, a PI3-kinase inhibitor, in pediatric patients 
24 
25 with neuroblastoma. Only after the initial phase I study, the subsequent phase II   design 
26 
27 will  test for  the use  of  SF1126 in  patients  with tumors  such  as  retinoblastoma   with 
28 
29 MYCN amplification, MYCN expression or Myc expression. Besides, a number of    early 
30 
31 clinical  trials  are  testing  IGF1R  targeting  in  pediatric  patients.  The  results  of these 
32 
33 targeting  approaches  will  reveal  the  efficacies  and  related  long-term  toxicities      of 34 
35 targeting these pathways in pediatric patients. It is important to note that these trial 
36 results of targeted therapies in pediatric patients may, in the near future, further guide 37 
38 the identification of related genetic biomarkers of response among potential pediatric 
39 
40 responders. 
41 
42 
43 
44 
45 There  are  documented  cases  of  exceptional  responders  to  targeted  therapies.   An 
46 
47 example  is  a  12-year-old  Caucasian  male  with  BRAF  V600E  mutant   glioblastoma 
48 
49 multiforme  [7]  who  achieved  complete  regression  of  tumor  in  response  to  a BRAF  
50 
51 
52 
53 18 
54 
55 
56 
57 
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9 inhibitor  (vemurafenib).  It is anticipated that  some of  these pathway inhibitors can    be 
10 
11 clinically effective in pediatric solid tumors with tolerable toxicity profile. 
12 
13 
14 
15 
16 Future Perspectives: 
17 
18 As of today, there are only 8 pediatric solid tumor types with whole-exome sequencing 
19 
20 data available. Among those, some of the studies have only very limited number of 
21 
22 cases being sequenced. It is anticipated that with additional 3 large scale sequencing 
23 projects ongoing, some new druggable genetic events may be uncovered for these 24 
25 often  aggressive  tumors,  which  often  lack  treatment  options.  Efforts  thus  far,  have 
26 
27 revealed  a  limited  number  of  potential  druggable  mutations  such  as  EGFR,    ALK, 
28 
29 PIK3CA, FGFR1, NF1, IDH1 and IDH2 mutations. These findings may help define new 
30 
31 clinical trial design, or pediatric basket-type of trials for these patients. Multi-center or 
32 
33 international efforts are often required for clinical trials to be conducted with   reasonable 
34 
35 patient  number for  the testing of  new agents for  these rare tumors.  Lastly,  it  is noted 
36 
37 that most of these published WES represent the genomic profiles of mostly Western 
38 
39 pediatric patients, therefore, additional sequencing efforts in more pediatric cancers 
40 from a more diverse ethnicity can be encouraged, which may facilitate a more global 41 
42 development of precision medicine for pediatric solid tumors worldwide. In conclusion, 
43 
44 current FDA-approved targeted therapies available for pediatric solid tumors are  grossly 
45 
46 insufficient. New pediatric gene-based clinical trials are urgently needed to provide the 
47 
48 impetus for the development of precision medicine for pediatric solid tumors. 
49 
50 
51 
52 
53 19 
54 
55 
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11 
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13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 Executive Summary: 
24 
25 
26 Exceptional   responders   in  pediatric   solid   tumors   shed   hope   for precision 
27 
28 medicine development 
29 
30 •    BRAF-mutated and ALK-mutated pediatric solid tumors have good clinical 
31 
32 responses in case reports. 
33 
34 •    Gives hopes for precision medicine for pediatric cancers with genomic profiling. 
35 
36 
37 WES studies in pediatric solid tumors 
38 
39 •    8 out of 11 most common pediatric solid tumors have potential druggable 
40 
41 genomic aberrations. 
42 
43 •    Main targets include: BRAF, EGFR, PIK3CA, NF1, IDH1, IDH2, MYCN, ALK, 
44 
45 FGFR1, FGFR4, and KIT. 
46 
47 Anticipating more WES data for more pediatric solid tumors 
48 
49 •    Many ongoing tumor-specific large scale WES studies 
50 
51 
52 
53 20 
54 
55 
56 
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8 
9 •    Many ongoing clinical multi-tumor type sequencing studies coupled with clinical 
10 
11 investigations of drug efficacy based on molecular profile and toxicity in children. 
12 
13 
14 Current Targeted Therapies for Pediatric Solid Tumors 
15 • Currently with only 3 approved targeted therapies for pediatric solid tumors. 16 
17 • everolimus for subependymal giant cell tumor for both children and adults 
18 
19 • dinutuximab for neuroblastoma for both children and adults 
20 
21 •    denosumab for giant cell tumor in skeletally mature adolescents and adults. 
22 
23 
24 Towards precision treatment for pediatric solid tumors 
25 
26 •    major   clinical   findings   investigating  the  feasibility  and  practical   issues    for 
27 
28 implementing  molecular  profiling  for  potential  precision  treatment  of  pediatric 
29 
30 cancers. 
31 
32 •    ~40% pediatric solid tumors have potential druggable targets 
33 
34 •    Some clinical responders have been reported together with genomic profiles 35 
36 •    Several ongoing major trials for precision medicine in the US and Germany 
37 
38 
39 Ongoing clinical trials for targeted therapies for pediatric solid tumors 
40 
41 
42 •    Ongoing clinical trials targeting BRAF, EGFR, ALK, ROS and MET have  included 
43 
44 genomics for children 
45 
46 •    Also ongoing clinical trials for EGFR, IGF1R, and PI3K pathway inhibitors do   not 
47 
48 include genomic profiling. 
49 
50 
51 
52 
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1 
2 Cancer Type 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
 
 
 
 
US Incidence 
rate (per 
100,000) 
 
 
 
 
Cases in 
US 
(2009-13) 
 
 
 
 
WES/ 
WGS/ 
Others 
 
 
 
 
 
Country 
(Cohort) 
 
 
 
 
 
Frequency of common mutations Other known genetic events Reference 
16 Low grade glioma 17.1* 7066* 
17 (2008-2012) 
18 
 
WES 
(N=286) 
 
 
WES 
 
U.S. 
(N.A.) 
 
 
U.S.,    Japan 
 
IDH1 (77.3%); TP53 (51.1%); ATRX (41.3%); CIC (19.6%); NOTCH1 (10.8%); FUBP1 (8.7%); 
PIK3CA (8.4%); NF1 (5.9%); EGFR (5.2%); PIK3R1 (4.9%); SMARCA4 (4.6%); PTEN (4.6%); 
ARID1A (4.2%); IDH2 (4.2%); ZBTB20 (3.5%); APOB (3.2%); FLG (3.2%); RYR2 (3.2%); BCOR 
(3.2%) 
 
− cbioportal 
 
 
 
[15] 
19 (N=30)    (N 
> 2) 
(Primary) 
21 
22 
23 WES (N=31)    (N 24 > 2) 
(N.A.) IDH1  (100%); TP53 (86.7%); ATRX (83.3%); CCDC91 (16.7%); TMPRSS15  (16.7%); SMARCA4 (13.3%); RPL21 (13.3%); OR5D14 (13.3%); DCHS2 (13.3%); ZNF280D (13.3%); HOXC12 (13.3%); 
DYTN (13.3%); TRIM52 (13.3%); PCLO (13.3%); TJP3 (13.3%); ZNF628 (10%); OR6C70 (10%); 
SOWAHC (10%); CD3EAP (10%); TAAR8 (10%); MUC6 (10%); APOB (10%); FLG (10%); RYR1 
(10%); CCT8L2 (10%); CDKAL1 (10%); RFX7 (10%); OR5B3 (10%); WDR1 (10%); ADGRG7 (10%); 
GMNC (10%); SUGCT (10%); FAM189A2 (10%); NUP188 (10%); LRRC16B (10%); AIM2 (10%); 
AATK (10%); ABHD6 (10%) 
(Recurrent) IDH1 (100%); TP53 (93.6%); ATRX (80.7%); FAT1  (25.8%); KMT2C (22.6%); CDHR3 (22.6%); 
25 SMARCA4 (19.4%); ARNT (19.4%); MAP10 (19.4%); ATP2B4 (19.4%); MYO7B (19.4%); BCL11B (19.4%); HEPH (19.4%); SPHKAP (16.1%); MUC6 (16.1%); MARS (16.1%); FLG (16.1%); RAD54B 
26 (16.1%); STXBP5 (16.1%); NOTCH2 (16.1%); CDKN2A (16.1%); TMEM63B (16.1%); ABCB4 (16.1%); COL12A1 (16.1%); PIK3CA (16.1%); BRIP1 (16.1%); OBSCN (16.1%); TEX11 (16.1%); 
27 FBN3 (16.1%); COL28A1 (12.9%); MYOM1 (12.9%); SIGLEC1 (12.9%); ACSF2 (12.9%); TIMELESS 
(12.9%); CPNE3 (12.9%); AHNAK2 (12.9%); TAF1L (12.9%); OGFR (12.9%); TRRAP (12.9%); 
CRTAP (12.9%); DCHS2 (12.9%); MYH10 (12.9%); DDR1 (12.9%); ZNF211 (12.9%); STAT5A 
(12.9%); SETD1A (12.9%); ASPM (12.9%); SPEN (12.9%); HLA-B (12.9%); NUP133 (12.9%); 
ZNF107 (12.9%); KMT2D (12.9%); RNF213 (12.9%); BRD4 (12.9%); KAT6B (12.9%); PREX1 
(12.9%); SLC22A25 (12.9%); RELN (12.9%); TMPRSS15 (12.9%); LAMB1 (12.9%); PTPN13 
(12.9%); KRT12 (12.9%); ABL1 (9.7%); ACHE (9.7%); SLC9A5 (9.7%); SNRPB (9.7%); CTNNAL1 
(9.7%); SNAPC4 (9.7%); RNGTT (9.7%); ERBB4 (9.7%); C10ORF12 (9.7%); EPHB3 (9.7%); EPC2 
(9.7%); EYA2 (9.7%); FBXL5 (9.7%); CDC16 (9.7%); ZPR1 (9.7%); NES (9.7%); PTGDR2 (9.7%); 
32 PSTPIP1 (9.7%); WFDC12 (9.7%); APOB (9.7%); MAP3K1 (9.7%); APC (9.7%); TRIOBP (9.7%); DENND2D (9.7%); RYR1 (9.7%); ATM (9.7%); ZFHX3 (9.7%); KMT2A (9.7%); SART1 (9.7%); 
33 RBM14 (9.7%); ARID1A (9.7%); INTS5 (9.7%); EPHA10 (9.7%); SEC24B (9.7%); GIGYF1 (9.7%); 
KDM5C (9.7%); CAPN12 (9.7%); TCEB3 (9.7%); TMEM214 (9.7%); TOPAZ1 (9.7%); BPGM (9.7%); 
 
35 
36 
TET2 (9.7%); MDH1B (9.7%); TEAD3 (9.7%); SLC9A4 (9.7%); C5 (9.7%); PROL1 (9.7%); MYH1 
(9.7%); POLQ (9.7%); UPF2 (9.7%); IRS4 (9.7%); CBL (9.7%); ATRN (9.7%); NF1 (9.7%); AKR1D1 
(9.7%); RANBP17 (9.7%); GRIN2A (9.7%); STYK1 (9.7%); KMT2B (9.7%); HSPA5 (9.7%); 
TAS2R30 (9.7%); POLE (9.7%); CFTR (9.7%); MYO18A (9.7%); ADGRE3 (9.7%); MAGI2 (9.7%); 
COL1A1 (9.7%); WHSC1 (9.7%); MED12 (9.7%); WNT2B (9.7%); MAST3 (9.7%); SGK223 (9.7%); 
VIL1 (9.7%); ARHGAP9 (9.7%); TYW1B (9.7%); DYTN (9.7%); PRSS48 (9.7%); CPA2 (9.7%); PEX6 
(9.7%); CREBBP (9.7%); CR2 (9.7%); COL11A1 (9.7%); COL7A1 (9.7%); PCLO (9.7%); COL3A1 
(9.7%); CDAN1 (9.7%); PPP1R21 (9.7%); OR10AG1 (9.7%); PLS3 (9.7%); AKAP9 (9.7%); GAGE2D 
41 (9.7%); CTSV (9.7%); PLEC (9.7%); YTHDF2 (9.7%); PHF2 (9.7%); SCARA3 (9.7%); GPRC6A (9.7%); LRRK2 (9.7%); FAT4 (9.7%); SYNE1 (9.7%); IL23R (9.7%); UNC45A (9.7%); UBQLNL 
42 (9.7%); FSCB (9.7%); ITGAD (9.7%); NUP214 (9.7%); INPPL1 (9.7%); TSHZ3 (9.7%); NOB1 
(9.7%); USP35 (9.7%); DEFB126 (9.7%); LPA (9.7%); DSCAM (9.7%); SLC26A3 (9.7%); EPHA6 
(9.7%); NCOR2 (9.7%); PRDM2 (9.7%); LAMA2 (9.7%); KIAA1217 (9.7%); LCK (9.7%); EPS8L3 
44 (9.7%); PTPRD (9.7%); ARC (9.7%) 
45 
46 
47 Neuroblastoma 8.4** 3438** WES 
48 (N=87) 
 
Amsterdam 
(Children) 
 
ZNF717 (6.9%); ALK (5.7%); TIAM1 (3.4%) − [17] 
WES 
49 (N=56) 
50 
51 
52 
53 
54 
55 
56 
Germany 
(Children) 
ALK (8.9%); MUC16 (5.4%); WWP1 (3.6%); AHNAK2 (3.6%); MYH1 (3.6%); TTN (3.6%); ITGAE 
(3.6%); COL5A3 (3.6%); BAIAP2L2 (3.6%); LATS2 (3.6%); GJA3 (3.6%); PCDHB12 (3.6%); XIRP2 
(3.6%); MUC17 (3.6%); GIGYF2 (3.6%); DSC2 (3.6%); NEB (3.6%); KRT10 (3.6%); LHCGR (3.6%); 
HGSNAT (3.6%); TNXB (3.6%); TBP (3.6%); PDE6A (3.6%); SNX21 (3.6%); CASR (3.6%) 
− [18] 
Wilm's tumor 6.4** 2604** WES + 
57 WGS 
U.S. 
(Children) 
DROSHA (10.4%); CTNNB1 (6.5%); SIX1 (5.2%); WT1 (3.9%); WTX (3.9%); DGCR8 (3.9%) − [24] 
      
                                            
                
  
 
 
 
 
 
                  
      
 
                     
                   
                
 
        
     
 
20 
28 
29 
30 
31 
34 
37 
38 
39 
40 
WGS + U.S. BRAF  (12.0%); H3F3A  (4%);  FGFR1  (duplication/mutation/rearrangement; 21.3%) − [16] 
Other (Children)    
 WES + WGS + Other U.S. (Children) ALK  (9.2%) − [19] 
Retinoblastoma 3.3** 1336** WGS 
(N = 4) 
U.S. 
(Children) 
RB1  (100%) − [20] 
 
Glioblastoma 
multiforme 
1.6* 659* 
(2008-2012) 
WES 
(N=290) 
U.S. 
(N.A.) 
PTEN  (31.4%); TP53  (29.3%); EGFR  (26.8%); FLG  (11.5%); PIK3R1  (11.5%); NF1  (11.2%); 
PIK3CA  (11.2%); RYR2  (10.1%); PCLO  (9.8%); SPTA1  (9.4%); RB1  (8.7%); MUC17  (8%); 
− cbioportal 
 AHNAK2  (6.6%); ATRX  (5.9%); FRG1BP  (5.9%); TCHH  (5.6%); OBSCN  (5.6%); IDH1  (5.2%); KEL  (5.2%); CNTNAP2  (4.9%); SYNE1  (4.9%); KRTAP4-11  (4.5%); RELN  (4.5%); NLRP5  (4.2%);  CFAP47  (4.2%); STAG2  (4.2%); FLG2  (4.2%); COL1A2  (4.2%); HCN1  (4.2%); MROH2B  (4.2%);  POTEC  (3.8%); SCN9A  (3.8%); GABRA6  (3.8%); KMT2C  (3.8%); CDH18  (3.8%); SEMA3C  (3.8%);  PDGFRA   (3.8%); DMD  (3.8%); PRDM9  (3.5%); ABCB1  (3.5%); ABCC9  (3.5%); SEMG1  (3.1%);  RPSAP58  (3.1%); F5  (3.1%); TAF1L  (3.1%); ADAM29  (3.1%); LZTR1  (3.1%); THSD7B  (3.1%);  GRIN2A  (3.1%); PCDH11X  (3.1%); PIK3C2G  (3.1%); KDR  (3.1%); ADAMTS16  (3.1%); DSG3  (3.1%)  
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1 
2 
3 
4 
5 
6 
Osteosarcoma 5.0** 2056** WGS 
(N=34) 
 
 
 
 
 
 
 
 
 
 
 
 
 
U.S. 
(Children) 
 
 
 
 
 
 
 
 
 
 
 
 
 
TP53 (82.4%); DLG2 (52.9%); RB1 (29.4%); ATRX (29.4%) N.A. [30] 
Others − − Mutation: TP53; RB1 
Amplification: RUNX2 (87%); COPS3 ; PMP22 ; 
MAPK7 (20-78%); MYC (14-67%); E2F3 (60%); 
MDM2 (3-25%); VEGFA (25%) 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
[31] 
7 
8 
9 
 Others − − Mutation:  WT1; WTX; WT2 region(possible genes 
IGF2, CDKN1C, H19) 
CTNNB1; TP53; FWT1; FWT2; FBXW7 (4%) 
Deletion:  MEOX2; SOSTDC1; SKCG-1 
Amplification:  MYCN ; CACNA1E 
[25-27] 
Hepatoblastoma 1.8** 758** Others − − Mutation:  APC; CTNNB1; AXIN1; AXIN2; PIK3CA; 
GPC3; NSD1; TP53 
[28,29] 
    Deletion:  SMARCB1      Amplification:  PIK3C2B; PLAG1   
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1 
2 Table 1. Current FDA-approved targeted therapies for pediatric solid tumors. 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
 
Cancer Type 
 
Subtypes 
FDA approved targeted therapy drugs 
For children For adults 
CNS tumors Medulloblastoma 
Glioblastoma multiforme 
Low grade glioma 
Others 
- - 
- Bevacizumab 
- - 
Everolimus Everolimus (Subependymal 
(Subependymal giant  giant cell tumor) 
cell tumor, age > 3) 
Neuroblastoma - Dinutuximab Dinutuximab (FDA approval 
based on clinical trial 
involving pediatric patients) 
Retinoblastoma - - - 
Wilms' tumor - - - 
Hepatic tumors Hepatoblastoma - - 
Bone tumors Osteosarcoma - - 
Ewing's sarcoma - - 
Others Denosumab Denosumab 
(Giant cell tumor, (Giant cell tumor) 
skeletally mature 
adolescents) 
Soft tissue sarcomas Rhabdomyosarcoma - Pazopanib hydrochloride 
Germ cell tumors - - - 
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1 
2 Table 2: Clinical responders reported in early clinical trials in pediatric solid tumors. 
3 
4 Cancer type Genomic aberration(s) reported Response 
5 
6 
7 
8 
9 
 
 
 
Duration of 
response Drug Ref 
10 Infantile fibrosarcoma Chr3q copy loss, chr16 copy gain; STAG2 
11 (p.Y355F) mutation, IL-3 indel, Homozygous 
12 deletion CDK2NA , CDKN2B , LMNA-NTRK1 
13 fusion, NTRK1 , LMNA overexpression 
Partial remission N/A ALK inhibitor 
(crizotinib) 
[62] 
14 Renal cell carcinoma CDKN2A/2B copy loss, PPM1D frame-shift 
15 insertion (9p.T506fs), ASPSCR1-TFE3 fusion 
16 
17 
Stable disease 10 months pazopanib [62] 
18 Nasopharyngeal 
19 carcinoma 
KRAS  p.G12D, BRAF p.G469E No evaluable disease 6 months Raf inhibitor [62] 
20 Epithelioid inflammatory 
21 myofibroblastic sarcoma 22 
23 
24 
RANBP2-ALK fusion complete metabolic and 
anatomic response at 8 
months later after initial 
treatment 
N/A ALK inhibitor 
(crizotinib) 
[80] 
25 Myofibroblastic sarcoma  CARS-ALK fusion Complete remission for 
26 9 months after end of 
27 therapy. Then relapse, 
28 again response to ALK- 
29 inhibitor. 
30 
9 months ALK inhibitor 
(ceritinib) 
[72] 
31 Diffuse intrinsic pontine 
32 glioma 
33 
MET Amp, PDGFRA Amp, TSC2  p.V1312fs, 
PTEN del, H3F3A p.K27M, TP53  p.R273C 
Partial response 9 months   Everolimus, 
imatinib and 
crizotinib 
[72] 
34 Undifferentiated sarcoma PIK3CA p.E545K, TP53 p.R306X Complete remission CR (till end of 
35 
36 follow-up) 
Sirolimus [72] 
37 Medulloblastoma PTPRZ1-MET fusion, TP53 p.T125R Mixed response N/A ALK inhibitor 
38 (crizotinib) 
[72] 
39 Anaplastic 
40 pilocyticastrocytoma 
41 
42 
43 
44 
45 
46 
47 
48 
49 
FAM131B-BRAF fusion Stable disease N/A MEK inhibitor 
(trametinib) 
 
 
 
 
 
https://mc04.manuscriptcentral.com/fm-fon 
[72] 
Perivascular epithelioid 
cell tumor 
SFPQ-TFE3  fusion 90% tumour reduction 16 months pazopanib [62] 
Wilms tumor AMER1 deletion, MYC  p.P44L, MAX  p.R60Q Partial response > 15 months VEGF2   inhibitor 
(XL-184) 
[62] 
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1 
2 Table 3. Clinical trials with integrated tumor genetic aberrations as criteria in trial design. 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60
in Trial design  NCT Phase Drugs Condition Eligibility Specifications BRAF BRAF NCT01677741 1 Dabrafenib Neoplasm, Brain 12 mo - 17 yrs BRAF V600  mutation 
 
 NCT00198159 2 Gefitinib Germ cell tumors ≥ 15 yrs EGFR expression 22 ALK ALK NCT00939770 1, 2 Crizotinib Brain & CNS tumors 1 - 21 yrs ALK  fusion proteins 
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5 
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1 
2 Table 4. Ongoing clinical trials for targeted therapies with no inclusion of genetic analysis in trial design. 
3 Genes 
4 involved in Trial 
5 design 
 
 
Drug target 
Pediatric clinical trials 
 
Drug NCT Phase Condition Eligibility Specifications 
6 None EGFR Cetuximab NCT00148109 2 Sarcoma ≥ 16 yrs  Arm 1: EGFR positive Arm 2: EGFR negative 
Erlotinib NCT00124657 1, 2 Brain & CNS tumors 3 - 21 yrs - 
8 Erlotinib NCT00418327 1 Malignant brain tumor 
9 Brain stem glioma 
1 - 21 yrs - 
Erlotinib NCT00360854 1 Brain & CNS tumors 1 - 21 yrs - 
10 Erlotinib + 
11 Sirolimus 
NCT01962896 2 Germ cell tumors 
(except pure mature teratoma) 
12 mo - 50 yrs - 
Gefitinib NCT00040781 1 Unspecified childhood tumor, protocol specific ≤ 21 yrs No primary CNS tumors or known 
12 metastases to the CNS 
13 Gefitinib NCT00042991 1, 2 Gliomas 3 - 21 yrs In combination with radiation therapy 
Nimotuzumab NCT00600054 2 Diffuse pontine glioma 3 - 18 yrs  - 
14 Nimotuzumab NCT00561691 3 Diffuse intrinsic pontine glioma 3 - 20 yrs - 
15 Vandetanib + 
Dasatinib 
NCT00996723 1 Diffuse intrinsic pontine glioma 18 mo - 21 yrs Administered during and after radiation 
therapy 
16 IGF1R Cixutumumab NCT00609141 1 Ewing's sarcoma 
17 Peripheral primitive neuroectodermal tumor 
Unspecified childhood solid tumor, protocol 
specific 
19 
1 - 21 yrs No CNS tumor or lymphoma 
Cixutumumab NCT00831844 2 Solid tumors 7 mo - 30 yrs No known CNS metastases 
20 Cixutumumab + 
21 Temsirolimus 
Cixutumumab + 
Temsirolimus 
NCT00880282 1 Unspecified childhood tumor, protocol specific 1 - 21 yrs - 
 
NCT01614795 2 Sarcomas 1 - 30 yrs No known CNS metastases 
23 Figitumumab NCT00474760 1 Ewing's sarcoma ≥ 9 yrs - 
Ganitumab NCT00563680 2 Ewing's family tumors 
Desmoplastic small round cell tumors 
≥ 16 yrs No known brain metastases 
25 RG1507 NCT00560144 1 Neoplasms 2 - 17 yrs - 
26 SCH717454 NCT00617890 2 Osteosarcoma Ewing's sarcoma 
27 Peripheral neuroectodermal tumor 
≥ 4 yrs No leptomeningeal or CNS metastases 
28 PI3 kinase SF1126 NCT02337309 1 Neuroblastoma 1 - 30 yrs SF1126, a novel inhibitor of PI3 kinase and mTOR. After a recommended 
29 pediatric dose is identified, phase 2 
30 follows with treatment of patients with MYCN amplification or expression. 
31 
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